Study confirms rare CYP2C19 and CYP2D6 variants reduce drug-metabolizing activity
A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the drug-metabolizing enzymes ...
Jan 29, 2026
0
0









